Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) AI Stock Analysis

• Market Cap: AU$59.53B
• Dividend Yield: 0.82%
• Average Volume (3M): 1.03M
• Price to Earnings (P/E): 27.7
• Beta (1Y): 0.89
• Revenue Growth: 11.26%
• EPS Growth: 39.47%
• Country: AU
• Employees: 9,980
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.39
• Shares Outstanding: 1,464,148,300
• 10 Day Avg. Volume: 1,009,171
• 30 Day Avg. Volume: 1,031,751
• PEG Ratio: -0.31
• Price to Book (P/B): 6.36
• Price to Sales (P/S): 7.38
• P/FCF Ratio: 23.01
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$46.66
• Price Target Upside: 14.36% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 11

• Rating: 71 Outperform
• Price Target: AU$45.00 ▲(10.29% Upside)

Resmed Inc's strong financial performance and positive earnings call sentiment are the primary drivers of the stock score. However, bearish technical indicators and a relatively high P/E ratio suggest caution. The company's strategic initiatives and shareholder return plans provide a positive outlook, but market competition and valuation concerns temper the overall score.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand and effective product portfolio management, supporting long-term business expansion.

Innovation and Product Development

Ongoing innovation in AI and digital products enhances ResMed's competitive edge, driving future growth and market leadership in digital health.

Launch of Sleep Institute

The Sleep Institute initiative positions ResMed as a leader in sleep health research, potentially leading to new insights and product advancements.

Negative Factors

Competitive Bidding Concerns

Uncertainties in competitive bidding could impact pricing and margins, posing risks to ResMed's financial performance in the DME space.

Challenges in U.S. Mask Market

Intense competition and market dynamics in the U.S. mask market may pressure ResMed's market share and profitability in this segment.

Asset Utilization

Decreased return on equity suggests inefficiencies in asset utilization, which may hinder ResMed's ability to maximize shareholder value.

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Business Overview & Revenue Model

Company Description

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME)to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; and HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies. The company markets its products primarily to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

How the Company Makes Money

ResMed Inc. generates revenue through the sale of its respiratory care devices, such as continuous positive airway pressure (CPAP) machines, masks, and related accessories used for the treatment of sleep apnea and other respiratory disorders. In addition to device sales, ResMed earns income from its software-as-a-service (SaaS) solutions, which include cloud-based platforms for healthcare providers to manage patient data and treatment efficacy. The company also benefits from strategic partnerships with healthcare organizations and ongoing investments in research and development to enhance its product offerings and expand its market reach. Factors contributing to ResMed's earnings include an increasing global awareness of sleep-related health issues and a growing demand for remote patient monitoring and management solutions.

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Financial Statement Overview

Summary

Resmed Inc demonstrates strong financial health with consistent revenue and profit growth, efficient cost management, and robust cash flow generation. The company maintains a low leverage and high equity ratio, providing financial stability, though there is room for improvement in asset utilization to enhance return on equity.

Income Statement

Resmed Inc has demonstrated consistent revenue growth over the years, with a notable increase of 2.49% in the latest period. The company maintains strong profitability metrics, with a gross profit margin of 59.36% and a net profit margin of 27.22%. EBIT and EBITDA margins are also robust at 32.79% and 37.37%, respectively. These figures indicate efficient cost management and strong operational performance.

Balance Sheet

The balance sheet reflects a healthy financial position with a low debt-to-equity ratio of 0.14, indicating conservative leverage. The equity ratio stands at 73.00%, showcasing strong equity financing. However, the return on equity has slightly decreased from previous years, suggesting a need for improved asset utilization.

Cash Flow

Cash flow analysis reveals a positive trend, with a free cash flow growth rate of 5.54% in the latest period. The operating cash flow to net income ratio is 1.72, indicating strong cash generation relative to net income. The free cash flow to net income ratio remains high at 0.94, reflecting efficient cash management.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	5.15B	5.15B	4.69B	4.22B	3.58B	3.20B
Gross Profit	3.05B	3.05B	2.66B	2.36B	2.02B	1.84B
EBITDA	1.81B	1.92B	1.53B	1.36B	1.18B	1.10B
Net Income	1.40B	1.40B	1.02B	897.56M	779.44M	474.50M
Balance Sheet
Total Assets	8.17B	8.17B	6.87B	6.75B	5.10B	4.73B
Cash, Cash Equivalents and Short-Term Investments	1.21B	1.21B	238.36M	227.89M	273.71M	295.28M
Total Debt	851.81M	851.81M	873.93M	1.58B	917.55M	793.72M
Total Liabilities	2.21B	2.21B	2.01B	2.62B	1.74B	1.84B
Stockholders Equity	5.97B	5.97B	4.86B	4.13B	3.36B	2.89B
Cash Flow
Free Cash Flow	1.66B	1.65B	1.29B	559.30M	195.11M	619.89M
Operating Cash Flow	1.75B	1.75B	1.40B	693.30M	351.15M	736.72M
Investing Cash Flow	-200.04M	-200.04M	-269.78M	-1.16B	-229.92M	-158.46M
Financing Cash Flow	-606.25M	-606.25M	-1.12B	422.87M	-128.36M	-764.63M

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 40.80
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:RMD, the sentiment is Neutral. The current price of 40.8 is below the 20-day moving average (MA) of 42.62, below the 50-day MA of 42.03, and above the 200-day MA of 38.39, indicating a neutral trend. The MACD of -0.44 indicates Positive momentum. The RSI at 37.43 is Neutral, neither overbought nor oversold. The STOCH value of 16.14 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:RMD.

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PME	73 Outperform	30.74B	266.72	44.84%	0.19%	31.88%	39.10%
SHL	73 Outperform	11.13B	21.06	0.00%	4.75%	9.63%	-0.37%
RMD	71 Outperform	AU$59.53B	27.71	26.44%	0.82%	11.26%	39.47%
COH	70 Outperform	19.80B	50.94	19.94%	1.79%	4.32%	9.24%
RHC	61 Neutral	7.75B	1,139.86	0.00%	2.37%	6.76%	-99.22%
SIG	56 Neutral	34.45B	59.29	-1.65%	0.43%	45.73%	-231.34%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Corporate Events

Resmed Inc Announces Proposed Sale of Securities by Officer

Resmed Inc has announced a proposed sale of securities under Rule 144, involving the sale of 8,009 common shares by Michael J. Farrell, an officer and director of the company. The transaction, facilitated through Fidelity Brokerage Services LLC, is set to take place on September 8, 2025, with an aggregate market value of approximately $2,227,590.84. This sale follows previous transactions by Farrell within the past three months, reflecting a strategic decision that may impact the company’s stock liquidity and stakeholder interests.

The most recent analyst rating on (AU:RMD) stock is a Buy with a A$47.25 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.

Resmed Inc Reports Decrease in CDIs for August 2025

Resmed Inc announced a net decrease in the number of CHESS Depositary Interests (CDIs) issued over quoted securities for August 2025, with a reduction of 4,204,410 CDIs compared to the previous month. This change is attributed to net transfers between CDIs and common stock on the NYSE, as well as activities related to stock options, restricted stock units, employee stock purchase plans, and share repurchases. The announcement reflects the company’s ongoing management of its securities and may impact its market positioning and stakeholder interests.

The most recent analyst rating on (AU:RMD) stock is a Buy with a A$47.25 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.

ResMed Inc Announces Proposed Sale of 3,000 Common Shares

ResMed Inc has filed a notice of proposed sale of securities, indicating the sale of 3,000 common shares with an aggregate market value of $812,310. The shares are scheduled for sale on the NYSE on September 2, 2025. This transaction involves shares acquired through options granted in 2018 and restricted stock vesting in 2022, reflecting strategic financial management and potential liquidity adjustments by the company’s officer, Brett Sandercock.

The most recent analyst rating on (AU:RMD) stock is a Buy with a A$47.25 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.

ResMed CFO Acquires Shares Following Performance Milestone

ResMed Inc.’s Chief Financial Officer, Brett Sandercock, reported a change in beneficial ownership with the acquisition of 5,462 shares of ResMed common stock on August 15, 2025. This transaction reflects the vesting of performance-based restricted stock units, indicating the company’s achievement of certain performance metrics, which may positively impact stakeholder confidence and demonstrate strong company performance.

The most recent analyst rating on (AU:RMD) stock is a Buy with a A$51.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.

ResMed Director Executes Strategic Stock Transactions

ResMed Inc reported a change in beneficial ownership as Director John Hernandez executed transactions involving the company’s common stock. On August 18, 2025, Hernandez acquired 2,575 shares through stock options at a price of $148.90 and subsequently sold the same amount at a weighted average price of $287.10, reflecting strategic financial management. These transactions indicate active engagement by the company’s leadership in managing their equity positions, potentially impacting investor perceptions and market dynamics.

The most recent analyst rating on (AU:RMD) stock is a Buy with a A$51.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.

ResMed Inc’s Global Counsel Acquires Shares Under Performance Plan

ResMed Inc announced a change in beneficial ownership involving its Global General Counsel, Michael J. Rider, who acquired 2,941 shares of ResMed common stock. This acquisition was part of a performance-based restricted stock unit plan, highlighting the company’s commitment to aligning executive compensation with performance metrics, which could positively impact stakeholder confidence in the company’s governance practices.

The most recent analyst rating on (AU:RMD) stock is a Buy with a A$51.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.